Recipient/donor origin of antigen-specific TCCs derived from antigen-specific TCLs or from pools of positive wells recovered from LDAs
. | 3-5 mo after CBT . | . | 12-15 mo after BMT . | . | ||
|---|---|---|---|---|---|---|
| Patient no. . | HCMV . | CA . | HCMV . | CA . | ||
| CBT-sib | ||||||
| 1* | 0/6 | 0/2 | 0/1 | 0/2 | ||
| 2* | 1/10 | 0/1 | 2/3 | 0/1 | ||
| 3* | ND | 1/62 | ND | 2/13 | ||
| 4* | ND | 7/4 | ND | 4/1 | ||
| 5* | ND | 0/51 | ND | 0/47 | ||
| 6† | 6/8 | ND | 4/8 | ND | ||
| 9† | 15/0 | ND | 14/0 | ND | ||
| CBT-ud | ||||||
| 12* | ND | ND | 0/12 | ND | ||
| 13* | ND | 0/32 | ND | 0/16 | ||
. | 3-5 mo after CBT . | . | 12-15 mo after BMT . | . | ||
|---|---|---|---|---|---|---|
| Patient no. . | HCMV . | CA . | HCMV . | CA . | ||
| CBT-sib | ||||||
| 1* | 0/6 | 0/2 | 0/1 | 0/2 | ||
| 2* | 1/10 | 0/1 | 2/3 | 0/1 | ||
| 3* | ND | 1/62 | ND | 2/13 | ||
| 4* | ND | 7/4 | ND | 4/1 | ||
| 5* | ND | 0/51 | ND | 0/47 | ||
| 6† | 6/8 | ND | 4/8 | ND | ||
| 9† | 15/0 | ND | 14/0 | ND | ||
| CBT-ud | ||||||
| 12* | ND | ND | 0/12 | ND | ||
| 13* | ND | 0/32 | ND | 0/16 | ||